Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like FINRA changed the way they process corporate actions last summer. Now they take a much deeper look into the companies records and business. Before last summer they only did this at the request of the SEC or there were obvious red flags. Like with MSSV and Christensen.
Rule 6490(d)(3) lays out the conditions under which an SEA Rule 10b-17 Action or Other Company-Related Action may be considered deficient and hence may not be processed. The rule outlines several factors that FINRA could use to make such deficiency determinations.
Over time, I have occasionally discussed the FINRA corporate action review process, often highlighting concerns about possible regulatory overstepping. However, the fact is that there haven't been any regulatory or rule amendments to the process for many years, and so, there hasn't been much to comment on until now.
Though this may seem like a complaint, it is worth noting that the FINRA corporate action review process has become more stringent than ever before. Even simple corporate actions now take 3-4 months to process, with more complex cases often taking over a year. The extent of review and scrutiny has increased substantially. Companies should anticipate FINRA examining all current and historical corporate records and actions, outstanding debts/liabilities, shareholder records, and business descriptions and plans. Therefore, firms trading on OTC Markets and considering a corporate action should take into account this significant time factor and ensure that all records are properly organized well in advance.
Even FINRA doesn't tout 10 days to anyone, especially with this new portal. Its 20 business days tops, most taking 30-60.
And, if FINRA had "issues" to the extent implied here, they would just deny it. They're good at that. Most likely they're asking for some old data/documents that the company has to resurrect from the archives...
So far, they are batting a 1000. Although it all took longer, everything they said they would do, they did do. Everything...
14C was filed ~20 weeks ago. I can wait a few more weeks....
Everyone should reach out to IR before jumpingto false conclusions... they have always shared timely updates with me wheevwr I ask. And maybe some are late to the party, but they made good on LAHO like no one ever did on any OTC that I have ever heard of. That BuyBack saved my bacon. They did buy GSCG, they did consolidate debt, they did grow revenue, they did spin off the Numismatics biz, they did launch Cancun, + more. Pretty sure the PRs at GSCG continues to show promises kept. The name change is live at Nevada Secretary of State, and Yahoo Finance. So if FINRA needs a few extra weeks to sort this out.... giddyup!
Not at all... FINRA may still process the corporate action eventually. That in no way does not mean the SEC will not follow through with any info FINRA may have suppled. In fact, there have been several SEC suspension notices that give credit to FINRA for the info they provided.
..
Buyer Beware
Pump and dump
.
Sweet!! So when name change occurs, it’s all clear!
😂
Wonder what your item of fear l will be.
FINRA can process corporate actions within 10 days if there are no issues.
https://www.aigbelaw.com/securitiesinvestinglawblog/2020/11/19/finra
FINRA and the SEC work together to prosecute issuers when regulatory infractions occur. Because FINRA does not hold the legal authority to prosecute any individual, it actively engages in investigations surrounding market fraud and shares its findings with the authorities that do prosecute. In this way, FINRA plays a vital role in the prosecution of those who violate securities laws. Though its principal mandate is in broker-dealings, FINRA does exercise some oversight on over-the-counter markets, such as OTCQX, OTCQB, OTCBB or pinksheets. FINRA Rule 6490, which was enacted in September 2010, created specific requirements surrounding company changes.
This must be some type of EFFIN joke 100 shares takes this down 25%?
Anyone who thinks FINRA name and ticker change cannot take at least 6 months does not understand the delays with the new Gateway System.
I emailed MSSV to ask for an update. They told me they are simply waiting for FINRA…. There are no pending issues, FINRA is just telling them they are very backed up….. 🤷♂️
https://finance.yahoo.com/news/meso-numismatics-announces-progress-name-110100700.html
Love any good news like this, but what is the deal with FINRA?
2037 is going to be our year. Just need a little patience.
ok thanks but I got the confirmation from vstock transfer now (e-mail back), saying "Thank you for sending this transaction over. It will be logged and reviewed for processing. We will reach out if we require anything else.".
ok thanks but I got the confirmation from vstock transfer now (e-mail back), saying "Thank you for sending this transaction over. It will be logged and reviewed for processing. We will reach out if we require anything else.".
Lets get this show on the road. I want to see a buck or two.
Yes, I am hoping as much. I got a message from Schwab that my account would be set up on May 10, 2024. I'll will wait to setup my account. The way I have figured, I should not owe any tax on that transaction. I know that I did not buy any shares at .002 and the buyout was .002.
I am starting to setup up my income tax returns and will be ready to go once I get the rest of the data from Schwab. TDA was ZERO help to me.
Thanks again!
🚨 $MSSV
💰0.0360
Pink Current, AS: 100M, OS: 12M, US: 11M
Update Delay: 72 hours
Authorized Shares Updated:
🔴 6,500,000,000 (2024-04-12)
🟢 100,000,000 (2024-04-15)
Difference: -98.5% (-6.4B)
https://t.me/otcupdatesbot?start=forward69144
Try contacting LANS Holdings. According to the website, you missed the deadline. However, the share buyback forms are still available on the website. Towards the bottom of the company’s web page is the contact us option. I guess you can contact the firm in writing (with a very polite letter) via the web page and request permission to submit the buyback forms after the deadline or ask for the buyback deadline to be extended so you can submit the forms. Hopefully, the firm will say it is okay to submit the buyback forms or extend the deadline and you can get your money back. Since you missed the deadline, I probably wouldn’t start completing the buyback forms in Docusign until the firm confirms to you that it will honor your forms filed after the stated deadline or until the firm changes the deadline.
https://www.lans.holdings/
I haven't checked into this in years but had 2 million shares of laho. How do I go about getting any funds?
Give the TDA / Schwab representative the LANS Holdings CUSIP number. A CUSIP number is a unique identifier assigned to financial securities such as stocks, bonds, options, and mutual funds. It serves as a standardized way to identify individual securities, making it easier for traders, investors, and regulators to track and trade them. The LANS Holdings CUSIP number is located on the DWAC form from V-Stock. You submitted a copy of this form to surrender your shares. Once you give the representative the CUSIP number, TDA / Schwab should be able to find your historical purchase price and historical shares owned that you are unable to locate.
Also, were your LANS buyback proceeds wired to your TDA brokerage account or were the LANS buyback proceeds wired to a different financial institution such as a bank account outside of your TDA brokerage account?
Thanks for the information; I'll start an aggressive approach to my situation.
My funds were surrendered for payment. I never got a 1099 from TDA nor from the receiver of the shares. I tried several times to get TDA to provide information on the shares that the surrendered, i.e., the shares purchase price and 1099. Seems like TDA placed the share data in a big black hole. I tried to search back years but not dice. I hope to go to Austin, Texas to see if I can get help from them.
Anyway thanks.
MSSV SECURITY DETAILS
Share Structure
Market Cap Market Cap
501,559
04/12/2024
Authorized Shares
100,000,000
04/15/2024
Outstanding Shares
12,538,968
04/15/2024
Restricted
1,304,872
04/15/2024
Unrestricted
11,234,096
04/15/2024
Held at DTC
9,383,898
04/15/2024
Float
11,234,096
03/19/2024
10K posted and Authorized Shares updated on OTC Markets. Just need the name change now.
10K posted and Authorized Shares updated on OTC Markets. Just need the name change now.
That’s parsing it a tad…. They are a gatekeeper of sorts that process/review corporate actions, and often has a back and forth with entities prior to finally processing the action…. So it’s not technically an approval….
Funny game you have there though…. A delay in processing equals “it’s because it’s fraud” but if it’s processed, that doesn’t mean it’s not fraud…. Cool, what are we? 8 years in on calling this company a fraud? They’re still going, growing revenues….
FINRA does not approve anything. And they warn folks about people and companies that make that claim.
Be Wary of Announcements Regarding FINRA "Approval" of a Corporate Action
Companies undergoing a corporate action often issue a press release or other communication, such as a tweet or other social media post, to provide details of the change. For instance, a company might announce a new corporate name that reflects a change in product lines or business focus. However, in the past, some companies have used these publications to suggest that FINRA has somehow "approved" a corporate action or that a corporate action will be effective once FINRA approves it. To clarify, this is not the case: FINRA does not approve corporate actions.
Ok, fair enough….
No finra approval-fraud
Finra approval - no fraud
I agree to your terms
lol
MSSV did recently(yesterday, or today) update their profile on OTCMarkets to better reflect their business description(which is annoying it wasn’t done sooner)…. That may have been a question mark for FINRA…. They also changed their phone number, they possibly had an outdated number there before….
There could be a number of reasons causing the delay, and none of them have to do with “problems”
FINRA could certainly have questions…. That happens all the time. That does not mean there are problems.
Questions are a normal part of approval processes in a wide range of things…. The bank had questions for me to answer before they approved my mortgage, it caused a delay, but there were no problems.
Pretty basic stuff here, delays are annoying, but don’t really tell us anything, good or bad, but should always be expected in the OTC.
There is a Problem....
The Company anticipates that this Information Statement will be mailed to our stockholders on or about February 12, 2024. Therefore, the Company anticipates that the Name Change will be effective on or about March 4, 2024, or such later date as all conditions and requirements to effectuate the Name Change are satisfied. Notwithstanding the foregoing, we must notify the Financial Industry Regulatory Authority of the Name Change by filing the Issuer Company Related Action Notification Form no later than ten (10) days prior to the anticipated effective date of the Name Change.
FINRA's Role in OTC Corporate Actions
Federal securities regulations task FINRA with processing corporate action announcement requests by companies that trade in the over-the-counter (OTC) marketplace rather than on a national securities exchange. Corporate actions reportable to FINRA generally include mergers, a dividend or other distribution of cash or securities, stock splits and name and domicile changes.
FINRA's processing function helps to keep investors and the market informed of company corporate actions. However, FINRA is not responsible for approving or disapproving the action the company is taking. And FINRA does not review such requests for a company's compliance with any federal, state or other regulatory requirements. The public company is responsible for making sure their business decisions comply with all applicable laws and regulations.
Corporate actions for exchange-listed companies are handled by the exchange upon which a company is listed; and information on these corporate actions is available on the websites of the relevant exchanges.
FINRA says companies need to submit corporate action request 10 days prior to the effective date. So, what you say doesn't make sense. I've seen many corporate actions processed and on the daily list within those 10 days. Its only when there are PROBLEMS that it takes much longer and many of those just never happen.
.
Buyer Beware
..
It took 11 months for FB to change to META
lol, no….. I’ve been an investor in a few company name changes…. Quickest one I’ve seen was 60 or so days from public filing….. and that was the only corporate action taken…. The other ones had multiple corporate actions, and took significantly longer….
Many law firms are suggesting that FINRA would be required to process in 30 or 60 days following their final comment answer…. The reason they are advocating for this is, because FINRA is almost always fairly slow in their processing of corporate actions, and state changes have already taken place, leading to public disclosure discrepancies.
No offense, but you didn’t even know how form 4 works with PCAOB, so, I’m gonna say the portal set up for MSSV legal to check, is probably for the SEC, and FINRA to alert of concerns…. And you have an awful track record in analyzing these guys’ intentions, and actions…..
Are you intentional in using the word “defiantly”? Or are you trying to use “definitely”? This is the 3rd time I’ve seen you write this and unsure of the intent.
No open issues on the company’s SEC portal
I just checked Nevada SOS. They did the name change with them and the AS change. Though FINRA has not yet Processed the name change so is not official. And... The new AS of 100,000,000 is not reflected at OTCMarkets or in their last filing Feb 12 2024... Finra defiantly has unresolved issues with this.
https://www.otcmarkets.com/filing/html?id=17258664&guid=szQ-kWUl8lFaJth
https://esos.nv.gov/EntitySearch/BusinessInformation
.
Buyer Beware
..
Ugh!!! Yeah…. It started in 2020 I believe! Crazy that you inquired about it 6 days after the deadline….. that sucks man….
Did I miss the cutoff for reparations lol, fml
LAS VEGAS, NV, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a regenerative medicine company is pleased to announce that it will be undergoing a name change from Meso Numismatics Inc. to Regenerative Medical Technology Group Inc. to better reflect the company’s business. The Company will also change its authorized shares outstanding from the current 6.5 billion to 100 million shares. Please see the Information Statement on Schedule 14C filed by the Company on February 2, 2024, and other Company filings at www.sec.gov.
About Meso Numismatics: Meso Numismatics Corp is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun and is currently building another one in Dubai. The Company distributes stem cells and other regenerative based cell lines, and equipment internationally and also specializes in education and training physicians in the area of regenerative medicine.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
Forward-Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
The Cancun clinic is currently active and is finalizing its full build out, which will double its footprint by the end of February. The clinic is also comprised of a lab where stem cell cultures can be produced. The Cancun clinic currently offers numerous procedures for multiple indications including: hormone replacement, autoimmune, neurodegenerative, osteoarthritis, cardiovascular, aesthetic/anti-aging, hair transplant, sports medicine, spinal cord injury, MS, and autism. The Company is in the process of building out a clinic in Dubai that will offer similar procedures to those in the Cancun location. The Dubai clinic is expected to be fully operational by the end of the second quarter of this year.
The Company plans to close on two additional locations for new clinics, one by the end of the third quarter and one by the end of the fourth quarter of this year. Both of these clinics are expected to be operational by the end of the second quarter of 2025.
The Company also has a collaboration with an Istanbul based clinic where the Company refers patients and receives patient referrals on various patient procedures.
The Company operates in the stem cell therapy market, which is expected to grow from $11.2 billion in 2022 to $31.4 billion by 2030 according to Precedence Research. The Company has also entered the exosome market, which is expected to grow from $250 million in 2022 to $3.2 billion by 2032 according to Global Market Insights.
The Company is actively collaborating with leading research institutions, universities, and industry experts to accelerate the development and commercialization of regenerative medical solutions. These partnerships create a collaborative ecosystem that fosters scientific excellence and ensures that the Company remains at the forefront of innovation, contributing to medical advancements and expanding its range of products. With a global vision, the Company is dedicated to making a positive impact on healthcare worldwide. The company is exploring opportunities to expand its reach and make its cutting-edge medical procedures accessible to patients across borders.
"We are thrilled to be at the forefront of regenerative medicine, bringing hope to patients and pushing the boundaries of what is possible in biotechnology. Our commitment to innovation and collaboration underscores our mission to make a lasting impact on the lives of individuals facing challenging medical conditions," said David Christensen, CEO and President of the Company.
The driving forces behind Global Stem Cells Group's strategy to increase revenue in 2024 involve a multifaceted approach within the rapidly expanding stem cell therapy market. As the wholly-owned subsidiary of the Company, Global Stem Cells Group specializes in cutting-edge stem cell research collaborations and physician training. The key components contributing to revenue growth include:
Certified Training Courses for Physicians - Offering specialized and certified training courses to physicians, ensuring they are equipped with the latest knowledge and skills in stem cell therapies. The Company is internationally recognized as an expert in the field of stem cells and regenerative medicine.
Manufacturing and Sales of the Latest Technology, Supplies, and Equipment - Engaging in the production and sale of state-of-the-art technology, supplies, and equipment related to stem cell applications, catering to the needs of medical professionals in the field.
Research and Development of Clinical Protocols - Investing in research and development collaborations to create advanced clinical protocols for stem cell applications, enhancing the efficacy and safety of treatments.
Regenerative Medical Clinics - Cancun, Dubai, and Istanbul, Provide standardized regenerative medical treatments. These treatments cover a spectrum of health issues, including musculoskeletal disorders, autoimmune diseases, aesthetics, and anti-aging.
Franchising Network of Regenerative Medical Practitioners - Establishing a network of franchised regenerative medical practitioners, potentially increasing the geographical reach and accessibility of stem cell treatments. Currently 26 clinics in 21 countries carry the Company's banner. This allows the Company to raise its global profile and branding and assist the company in bringing patients to its own clinics.
Turnkey Solutions for Stem Cell Processing Center Installation & Management - Offering comprehensive complete solutions for the installation and management of stem cell processing centers, providing a one-stop solution for practitioners entering the field.
By diversifying into these key areas Global Stem Cells Group aims to tap into various aspects of regenerative medicine, creating revenue streams through education, product sales, research, patient services, and strategic partnerships within the stem cell therapy market.
"We are excited to announce our significant growth across multiple channels, showcasing the strength and diversity of our business. The success in training, product sales, equipment sales, and patient procedures reflects our commitment to excellence in every facet of regenerative medicine," said Benito Novas, CEO and Founder of Global Stem Cells Group.
This press release should be read in conjunction with all of the Company's filings on www.sec.gov
About Meso Numismatics: Meso Numismatics, Inc. is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun and is currently building another one in Dubai. The Company distributes stem cells and other regenerative based cell lines and equipment internationally and also specializes in educating and training physicians in the area of regenerative medicine.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |